Skip to content
TrialScanner

NCT01923428

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Phase 2/Phase 3CompletedARDXLead

Registry record

Lead sponsor
Ardelyx
Conditions
Constipation Predominant Irritable Bowel Syndrome
Primary completion
Oct 2014Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01923428 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01923428: The Efficacy of AZD1722 in... | TrialScanner